efficacy of 2013 ACC/AHA guideline in primary prevention of coronary artery disease (CAD)

A primary prevention trial of coronary artery disease risk factors modification by using 2013 ACC/AHA guidelines

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181003041218N1

Enrollment

322

Registered

2018-12-18

Start date

2014-04-04

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease. Chronic ischemic heart disease

Interventions

Intervention 1: Intervention group 1 : lifestyle modification according to 2013 ACC/AHA guideline in addition to Atorvastatin 20 mg for individual with RRS>7.5 and Hs-CRP>3. Intervention 2: Interventi

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: men and women aged over 20 years without previously diagnosed CAD

Exclusion criteria

Exclusion criteria: non compliance

Design outcomes

Primary

Measure	Time frame
Mean of systolic blood pressure in mm Hg from baseline. Timepoint: 10 months from baseline. Method of measurement: In clinic with standardized sphygmomanometer.;Mean change in diastolic blood pressure in mm Hg from baseline. Timepoint: 10 months from baseline. Method of measurement: In clinic with standardized sphygmomanometer.;Mean change in total cholesterol in milligram / deciliter from baseline. Timepoint: 10 months from baseline. Method of measurement: Laboratory enzymatic method.;Mean change in fasting blood sugar in milligram / deciliter from baseline. Timepoint: 10 months from baseline. Method of measurement: Laboratory enzymatic method.;Mean change in Reynolds risk score from baseline. Timepoint: 10 months from baseline. Method of measurement: statistical calculation method.	—

Measure

Time frame

Mean of systolic blood pressure in mm Hg from baseline. Timepoint: 10 months from baseline. Method of measurement: In clinic with standardized sphygmomanometer.;Mean change in diastolic blood pressure in mm Hg from baseline. Timepoint: 10 months from baseline. Method of measurement: In clinic with standardized sphygmomanometer.;Mean change in total cholesterol in milligram / deciliter from baseline. Timepoint: 10 months from baseline. Method of measurement: Laboratory enzymatic method.;Mean change in fasting blood sugar in milligram / deciliter from baseline. Timepoint: 10 months from baseline. Method of measurement: Laboratory enzymatic method.;Mean change in Reynolds risk score from baseline. Timepoint: 10 months from baseline. Method of measurement: statistical calculation method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zinat Hatmi

Tehran University of Medical Sciences

znhatmi@yahoo.com+98 21 6405 3220

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026